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Abstract
Background: The pleiotropic protein MIF, (macrophage migration inhibitory factor), has been
demonstrated to modulate several key proteins governing cell cycle control and is considered to
contribute to cell growth and differentiation. In this study we investigated the effect of MIF on the
expression and cellular distribution of the CDK inhibitor p21.
Methods: The effect of endogenous MIF on p21 expression and distribution was examined by
comparing murine dermal fibroblasts derived from wt and MIF -/- mice. The effect of MIF on cell
growth and apoptotic rates was compared using 3H-Thymidine incorporation assays and annexin
V/PI assays respectively. Total p21 protein levels were compared using flow cytometry and western
blotting. p21 mRNA was assessed by RT-PCR. Intracellular p21 staining was performed to assess
cellular distribution of total protein. To further confirm observations siRNA was used to
knockdown MIF protein in wt cells. Cell cycle analysis was performed using PI incorporation assays.
Results: MIF-/- murine dermal fibroblasts exhibited reduced proliferative responses and were
more susceptible to apoptosis. This was associated with reduced p21 expression and nuclear
distribution. Treatment with recombinant MIF protein was demonstrated to reduce both basal and
induced apoptosis and increase nuclear p21 expression. Reduced nuclear p21 expression was also
observed in MIF siRNA treated wt cells.
Conclusion: The results demonstrate that in the absence of MIF p21 expression and nuclear
distribution is reduced which is associated with a reduction in cell growth and increased apoptosis.
MIF may therefore play a role in maintaining homeostatic control of p21.
Background
Phase transition of the cell cycle is dependent upon the
ordered activation and subsequent assembly of cyclin-
dependent kinases (CDKs) with their regulatory subunit
proteins, cyclins. Quiescent cells are stimulated to pro-
duce cyclins in response to specific mitogenic signals. The
pro-proliferative activity of cyclin-CDK complexes are
tightly regulated by CDK- inhibitors (CKIs) that block the
catalytic activity of the holoenzymes. P21 is a member of
the Cip/Kip family of CKIs which also consists of p27 and
p57. p21 is therefore traditionally identified as a cell cycle
arrest protein. Its function in the p53 tumour suppressor
pathway as an inhibitor of G1 CDK's resulting in cell cycle
arrest in response to various cellular stresses is well
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investigations have revealed new roles for p21 in normal
cell cycle progression [3-6] and in active proliferation
[7,8].
Recent studies have shown that the proinflammatory
cytokine macrophage migration inhibitory factor (MIF) is
an important contributor to normal cell division as well as
oncogene-induced malignant transformation and tumor-
igenesis [9]. One mechanism through which MIF may
exert these effects is via escape from p53 mediated cell
cycle control. This concept is supported by studies from
our lab wherein recombinant MIF (rMIF) treatment leads
to decreased p53 protein expression as measured by West-
ern blotting [10]. MIF mediated escape from p53 effect is
also demonstrated in studies by Hudson et al where the
addition of either purified recombinant MIF or over-
expression of an ectopically expressed MIF could over-
come p53-induced growth arrest, senescence and apopto-
sis [11]. Similarly, MIF has shown to sustain the survival
of macrophages through suppression of p53 [12].
In this study we find that the absence of MIF impacts sig-
nificantly on the expression and cellular distribution of
p21. This observation was associated with a marked
reduction in cell growth and increased apoptosis, suggest-
ing a role for MIF in maintaining normal homeostatic
control of p21 expression and distribution.
Methods
Animals
MIF-/- mice were generated via homologous recombina-
tion in J1 embryonic stem cells as described previously
[13]. They were maintained on a mixed background of
129/Sv C57BL/6. MIF+/+ wild-type (wt) mice of the same
background were bred from MIF-/- littermates and used as
controls. Mice were housed in a conventional housing
facility. All animal experiments were performed in accord-
ance with the regulations of Monash University Animal
Ethics Committee.
Isolation and culture of murine dermal fibroblasts
Murine dermal fibroblasts (MDF) were obtained from
MIF-/- and wt mice. Dermal fibroblasts were isolated by
dissection of the dermal layer. A single cell suspension
was obtained by digesting minced dermal tissue with 2.4
mg/ml Dispase (grade II, 5 U/mg; Boehringer Mannheim,
Melbourne, Australia), 1 mg/ml collagenase (type II;
Sigma, Melbourne, Australia) and DNase (type I; Boe-
hringer Mannheim). MDF were propagated at a cell den-
sity of 15 × 106 cells per 10 cm culture plates in RPMI (ICN
Biomedicals, Cincinatti OH)/10% FCS (ICN Pty Ltd, Mel-
bourne, Australia) at 37°C in a 5% CO2 humidified incu-
bator. Cells were used between passages 4 and 14.
Comparisons between MIF-/- and wt cells were made
using cells of the same passage.
Fibroblast proliferation by 3H-Thymidine assay
MDF were seeded onto a 24 well plate at a density of 5 ×
104 cells/well (70% confluence) in RMPI (10%FCS) and
incubated for 24 hours at 37°C. Cells were then washed
twice with Hanks buffered saline solution (HBSS) before
starving in 500 ul RPMI (0.1%BSA) at 37C for 24 hours
and were then cultured for 30 hours in 10% FCS. Cells
were pulsed with 1 uCi/ml 3H/Thymidine in 50 ul RPMI
for 18 hours at 37°C. Radioactivity content was deter-
mined by scintillation counting using a Wallac 1409 Liq-
uid Scintillation Counter (3H/Thy, 60 seconds/tube).
DNA synthesis was estimated by measurement of 3H-Thy
incorporation in fibroblasts. Results were expressed as the
average CPM count with the standard error of the mean.
Fibroblast proliferation by cell count
Wt and MIF-/- MDF were seeded onto a 24 well plate at a
density of 5 × 104 cells/well (70% confluence) in RMPI
(10%FCS) and incubated for 72 hours at 37°C. At 24
hour time points, cells were washed with Hanks buffered
saline solution (HBSS) and removed by trypsinisation. A
single cell suspension was prepared 1:1 ratio with trypan
blue (Sigma) and counted using a haemocytometer.
Results were expressed as the total number of viable cells
(cell count).
Fibroblast apoptosis
Murine Dermal Fibroblasts (MDF) seeded onto a 6 well
plate at 2 × 105 cells per well in RPMI (10% FCS) and
allowed to adhere overnight. After 24 hours non adherent
cells were washed off in HBSS and each well was replen-
ished with RPMI (10% FCS) with or without SNP (0.50
mM)/(0.25 mM) and rMIF (100 ng/ml) treatment. 24
hours later apoptotic cells were differentiated by com-
bined application of annexin V-FITC and PI. Briefly, cells
were trypsinised, centrifuged and re-suspended in binding
buffer (10 mM HEPES/NaOH, 0.14 M NaCl, 2.5 mM
CaCl2, pH 7.5). Samples were incubated with annexin V-
FITC and PI for 30 min at room temperature and analysed
by flow cytometry. Annexin V-FITC and PI fluorescence
was detected in the FL-1 (green) and FL-2 (red) channels
respectively after correction to the spectral overlap
between the two channels. Apoptotic and necrotic cells
were distinguished on the basis of annexin V-FITC reactiv-
ity and PI exclusion. Live, non-apoptotic cells were not
stained with any of the reagents. Apoptotic cells exhibited
intense green (FITC) and low or intermediate red (PI) flu-
orescence (early and late stages of apoptosis, respectively).
Permeability of late apoptotic cells for PI is the conse-
quence of the compromised integrity of their plasma
membrane. Results are expressed as % apoptosis, the per-Page 2 of 10
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tive to total number of cells gated.
Detection of P21 in FLS by Western blotting
P21 expression in wt and MIF-/- MDF were compared
using Western blotting with a monoclonal antibody spe-
cific for p21 (F-5 Santa Cruz, CA). Briefly, cells taken from
semi confluent (70%) culture were washed with cold PBS
and then lysed with 2× SDS sample buffer. The protein
samples were boiled for 10 minutes and stored at -20°C.
Samples were subjected to 10% Tris Glycine iGel SDS/
PAGE (Gradipore, Sydney Australia), transferred to a
Hybond C membrane and detected using ECL detection
system (Amersham).
RNA extraction and real-time polymerase chain reaction 
(RT-PCR) analysis
Total RNA was extracted from MDF using TRIzol reagent
(Gibco BRL, Grand Island, NY), according to the manu-
facturer's protocol. Two micrograms of total RNA was
reverse transcribed using Superscript II reverse tran-
scriptase and oligo (dT)18 (Gibco BRL). PCR amplifica-
tion was performed on a LightCycler (Roche Diagnostics,
Castle Hill, Australia) by using SYBR Green I as a double-
stranded DNA-specific binding dye and continuous fluo-
rescence monitoring. MIF, p21 and β-actin PCR products
were purified on agarose gel electrophoresis using the
QIAEX II gel extraction system (Qiagen, Clifton Hill, Aus-
tralia). The level of expression of messenger RNA (mRNA)
of MIF and or p21 was determined relative to the standard
preparation using the LightCycler computer software.
For PCR, 5 μl each of the standard and the sample com-
plementary DNA dilutions were added to individual cap-
illary tubes. Amplification was carried out in a total
volume of 10 μl containing primer concentrations of 3
pmoles and 1 μl of dNTP mix, Taq, reaction buffer, and
SYBR Green I dye as supplied in the LightCycler DNA Mas-
ter SYBR Green I kit (Roche). Forty cycles of PCR were pro-
grammed. Relative quantification of target mRNA
expression was calculated and normalized to the expres-
sion of β-actin. The results, based on the ratio of target
mRNA to β-actin amplification, are presented as the fold
induction in mRNA expression relative to the amount
present in control samples.
Detection of p21 in murine fibroblasts by 
immunofluorescence
MDF were seeded on mini-slides placed within a 24 well
plate at a semi confluent density (70%) of 2.5 × 104 cells
per slide for 24 hours. Adherent cells were then washed
with HBSS, and fixed in 2% paraformaldehyde. Cells were
again washed and then permeabilised in 0.1% Triton X
(Sigma), or 0.1% Saponin (Sigma) for extranuclear stain-
ing, before being washed again in PBS/0.1% Na azide/
0.1% BSA and incubated with specific monoclonal anti-
body to p21 (F-5) or isotype-matched negative control
antibodies (Santa Cruz, CA) for 30 minutes. Unbound
antibody was removed by washing in PBS/0.1% Na azide/
0.1% BSA. Cells were then incubated for 30 minutes with
FITC conjugated-secondary antibody (Silenus, Mel-
bourne, Australia) before being washed and analysed
under UV microscope.
Detection of p21 in murine fibroblasts by flow cytometry
MDF taken from semi confluent culture were washed with
HBSS, and fixed in 2% paraformaldehyde. Cells were
again washed and then permeabilised in 0.1% Triton X
(Sigma) for 30 minutes before being washed again in PBS/
0.1% Na azide/0.1% BSA and incubated with specific
monoclonal antibody to p21 (F-5) or isotype-matched
negative control antibodies (Santa Cruz, CA) for 30 min-
utes. Unbound antibody was removed by washing in PBS/
0.1% Na azide/0.1% BSA. Cells were then incubated for
30 minutes with FITC conjugated-secondary antibody
(Silenus, Melbourne, Australia) before being washed and
analysed by flow cytometry. Results are expressed as delta
mean fluorescence intensity (ΔMFI)
For intracellular analysis of p21 protein by flow cytometry
0.05% Saponin was used to permeabilise the cell wall
leaving intracellular membranes intact. As above cells
were incubated with p21 antibody or negative control
antibody and analysed by flow cytometry. Nuclear p21
was estimated by subtracting ΔMFI of cytoplasmic p21
from ΔMFI of total p21.
SiRNA
RNA interference was used to knockdown MIF protein
expression by introducing a homologous double-
stranded RNA. The nucleotide sequences of dsRNA and
complimentary dsRNA for mouse MIF mRNA were 5'-
CCGCAACUACAGUAAGCUGdTdT-3' and 5'-CAGCU-
UACUGUAGUUGCGGdTdT-3', respectively. As a control
RNA duplex 5'-GCGCGCUUUGUAGGAUUCGdTdT-3'
and 5'-CGAAUCCUACAAAGCGCGCdTdT-3' were used.
MDF grown in RPMI 1640 with FCS (10%) were trans-
fected with either the MIF siRNA or the control RNA
duplex using Amaxa nucleofection electroporation
(Amaxa AG, Germany) according to the manufacturer's
protocol [14]. After 24 hours, cells were transfected with
either MIF siRNA or the control siRNA a second time. 24
hours after the second transfection the culture medium
was removed and cells were examined for p21 immun-
ofluorescence.
Cell cycle analysis
MDF taken from semi confluent culture via HBBS wash/
trypsinisation were resuspended in PBS before being
resuspended in ethanol and left on ice for 2 hours. ThePage 3 of 10
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decanted. The pellet was resuspended in a staining solu-
tion of 0.1% triton-X, DNase free RNase and Propidium
iodide (PI) for 30 minutes at room temperature. Samples
were then analysed by flow cytometry.
Data Analysis
ΔMFI was calculated by subtracting the mean fluorescence
of the samples stained with an isotype matched negative
control antibody from that of the samples stained with
specific antibodies. Results are expressed as the mean
+SEM. Statistical analysis was performed using the Stu-
dents t test. P < 0.05 was considered statistically signifi-
cant.
Results
MIF-/- cells exhibit reduced proliferative responses
To determine the role of endogenous MIF in cell growth
we examined proliferation in MIF-/- and wt MDF using a
3H-thymidine incorporation assay and cell count assay.
After a 42 hour analysis of 6 independent experiments we
found that cells lacking endogenous MIF displayed signif-
icantly reduced cell growth, (12437.9 +/- 1253.3), com-
pared to wt MDF (20841.7 +/- 2040.6) (Figure 1a). This
was confirmed by cell count assays which revealed signif-
icantly reduced numbers of viable MIF-/- cells compared
to wt over 24, 48 and 72 hours (Figure 1b).
MIF-/- cells are more susceptible to apoptosis
To further characterise the effects of endogenous MIF on
cell cycle profile, we examined apoptotic events in MIF-/-
and wt MDF by annexin V-FITC and PI dual labeling.
Compared with wt MDF, MIF-/- MDF were more prone to
undergo cell death exhibiting increased SNP induced
apoptosis, (63.8 +/- 5.5), compared to wt MDF, (36.7 +/-
5.2) (Figure 1c).
rMIF rescues cells from basal and SNP induced apoptosis
To explore the potential for exogenous MIF to alter cell
cycle events we examined both basal and induced apop-
totic events in MIF-/- and wt MDF with and without rMIF
treatment. Compared with control, treatment with rMIF
protein was demonstrated to significantly increase basal
survival and to significantly reduce SNP-induced apopto-
sis in MIF-/- MDF (Figure 2).
p21 expression is reduced in MIF-/- MDF
To examine the role of endogenous MIF in the regulation
of p21 levels, MIF-/- and wt MDF expression of p21 was
analysed using Western blotting and flow cytometry anal-
ysis. MIF-/- cells expressed lower levels of p21 protein
compared to wt MDF (Figure 3a, 3b). Accordingly P21
mRNA was reduced in MIF-/- MDF as determined by RT-
PCR (Figure 3c).
Subcellular localisation of p21 in MIF-/- MDF
To further explore the potential for MIF to influence p21,
we examined the subcellular localisation of p21 in MIF-/-
and wt MDF. Interestingly, MIF-/- MDF exhibited diffuse,
predominantly cytoplasmic p21 staining (Figure 4b) com-
pared to wt MDF, which displayed strong nuclear staining
for p21 (Figure 4a). Flow cytometric analysis of nuclear
p21 protein revealed a significant reduction in MIF-/-
compared to wt MDF (Figure 4c). Similar results were seen
in wt MDF spiked with MIF siRNA which exhibited a sig-
nificant reduction in nuclear p21 (figure 5b) compared to
control siRNA (Figure 5a). The efficiency of MIF knock-
down in wt MDF was quantified using RT-PCR. After 40
cycles of amplification MIF mRNA was not detectable in
samples transfected with MIF siRNA (figure 5c).
MIF-/- cells exhibit reduced proliferative responses and increased apoptosisFigure 1
MIF-/- cells exhibit reduced proliferative responses and increased apoptosis. a. Quantification of basal MIF-/- and wt 
MDF proliferation by 3H-thymidine incorporation. Significantly lower levels of thymidine incorporation were observed in MIF-/
- MDF compared wt MDF, (N = 5, * P < 0.05). b. Proliferation of MIF-/- and wt MDF further quantified by haemocytometric cell 
count over 72 hours (N = 4, * P < 0.05). c. Apoptosis of MDF in response to cellular stress induced by 0.5 mM SNP was 
assessed by flow cytometric analysis of annexin V-FITC and PI. Percentage apoptosis represents all non-viable cells, (N = 4, * P 
< 0.05).Page 4 of 10
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/- MDF
To further confirm the involvement of MIF in p21 redistri-
bution, MIF-/- and wt MDF were treated with rMIF and
examined for p21 by immunofluorescence. Randomly
cycling wt MDF from semi-confluent culture exhibited
predominantly nuclear localisation of p21 and rMIF treat-
ment of these cells did not yield any further increase in
nuclear p21 expression. However compared to vehicle,
rMIF induced a shift from predominantly cytoplasmic to
nuclear localisation of p21 protein in MIF-/- MDF demon-
strating MIF involvement in induction and nuclear trans-
location of p21 protein (Figure 6).
P21 redistribution is not the result of cell cycle phase 
differences
Cell cycle phase is well described to alter expression of key
cell cycle proteins including p21. To address this issue, we
examined the cell cycle phase profile of MIF-/- and wt
MDF taken from semi-confluent culture using flow cyto-
metric analysis of PI incorporation. No significant differ-
ence in the percentage of cells in each phase of the cell
cycle was seen. Therefore the difference in p21 expression
and subcellular localisation observed between MIF-/- and
wt MDF could not be explained by cell cycle phase differ-
ences between the cells in these experiments (Figure 7).
Discussion
MIF is a pro-inflammatory cytokine which is expressed
constitutively by almost all cell types and is significantly
upregulated in the setting of inflammatory stimulation
[15,16]. The findings in this study suggest that MIF is
involved in the promotion of normal cell cycle and prolif-
erative responses in murine dermal fibroblasts. Support-
ing this, recent studies have demonstrated a functional
role for MIF in normal cell division as well as cell survival
and oncogene-induced malignant transformation making
this cytokine an important new focus in tumour biology
research [17-19]. Evidence suggests that MIF may also
indirectly support tumour growth via promotion of ang-
iogenic responses [20,21]. Other studies have shown that
rMIF treatment or forced over expression of MIF can stim-
ulate cell growth [22]. A number of cell types have also
been shown to secrete MIF in response to growth factor
stimulation [23,24]. We have previously shown dose-
dependent regulation of human fibroblast proliferation
by rMIF [25].
In the current study, reduced proliferative responses in
MIF-/- MDF were associated with increased baseline and
SNP induced apoptosis. Moreover, treatment with recom-
binant MIF was associated with a reduction in SNP
induced apoptosis. This promotion of cell survival may
have relevance to inflammatory disease in terms of per-
sistence of inflammatory cells or growth of intrinsic cells
in an inflammatory lesion. For example endogenous MIF
has been shown to be important in promoting macro-
phage viability in the setting of inflammatory stimuli and
rMIF treatment or its overexpression in a variety of cell
types including fibroblasts, macrophages and endothelial
rMIF rescues cells from basal and SNP induced apoptosisFigur  2
rMIF rescues cells from basal and SNP induced apoptosis. The effect of rMIF on apoptosis of MDF was examined using 
cytometric detection of annexin V/PI dual labeling. MIF-/- MDF demonstrated increased rates of spontaneous apoptosis which 
was reduced following treatment with 100 ng/ml rMIF. Similarly, rMIF treatment abrogated SNP (0.25 mM) induced apoptosis 
in both MIF-/- and wt MDF, (N = 3, * P < 0.05).Page 5 of 10
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variety of stimuli [20,26]. Previous studies in our own lab-
oratory have shown that rMIF treatment of human fibrob-
lasts leads to rescue from SNP-induced apoptosis [10].
Consistent with this data, others have reported impaired
DNA damage response in cells lacking MIF [27].
Our finding in this study that genetic or siRNA mediated
deficiency of MIF is associated with reduced expression
and/or nuclear localisation of p21 and that rMIF treat-
ment induces nuclear localisation of p21 must be inter-
preted in the setting of emerging new literature regarding
this protein. p21 is traditionally conceptualised as a cell
cycle arrest protein. p53-induced nuclear accumulation of
high level p21 expression, resulting in G1 cell cycle arrest,
in response to various stressful stimuli, is well described in
the literature [1,2,28]. Evidence for an unexpected
requirement for basal expression of p21 in normal cell
cycle progression is however found in several recent stud-
ies [3-6]. p21-/- cells exhibit a failure of normal cell cycle
progression which has been related to a role for p21 as an
assembly factor which promotes cyclin-D1-CDK4 binding
thus contributing to cellular proliferation [29]. Moreover,
LaBaer et al 1997 demonstrated that p21 provides the
localisation signal for cyclin-D1-CDK4 nuclear import
[29]. Other studies have shown that p21 promotes
nuclear accumulation of cyclin-D1-CDK4 via its ability to
inhibit cyclin D1 nuclear export [4]. These studies suggest
some duality in p21 function with evidence for an unex-
Reduced p21 expression in MIF-/- cells compared with wtFig r  3
Reduced p21 expression in MIF-/- cells compared with wt. a. Levels of p21 expression in MIF-/- and wt MDF assessed by 
Western blotting using a monoclonal antibody to p21. The equivalence of protein loading was measured by detection of β-
tubulin. Each lane represents a single MIF-/- or wt MDF mouse. b. Flow cytometric detection of p21 protein in untreated MDF 
taken from semi-confluent culture. Results are representative of 4 independent experiments, each measuring at least 5000 
events. Expressed as delta mean fluorescence intensity (ΔMFI) which is the difference between the MFI of tested cells and the 
MFI of background staining (N = 4, * P < 0.05). c. Quantification of p21 mRNA to β-actin in MIF-/- and wt MDF by reverse tran-
scription polymerase chain reaction (RT-PCR).
Decreased nuclear p21 in MIF-/- MDF compared with wt MDFFigure 4
Decreased nuclear p21 in MIF-/- MDF compared with wt MDF. Immunofluorescent staining of p21 showing prominent 
nuclear localisation of p21 in wt MDF (a), in contrast to p21 expression in MIF-/- MDF showing diffuse staining in both the cyto-
plasm and nucleus (b). Reduced nuclear p21 protein expression was confirmed by flow cytometry (*P < 0.05) (c). In each group 
results are representative of 4 independent experiments.Page 6 of 10
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Cells spiked with MIF siRNA display reduced nuclear p21Figure 5
Cells spiked with MIF siRNA display reduced nuclear p21. In four separate experiments wt MDF nucleofected with MIF 
siRNA exhibited a significant decrease in nuclear p21 expression (b), while MDF nucleofected with control siRNA remained 
largely unchanged (a). The efficiency of MIF knockdown in wt MDF was quantified using RT-PCR. Compared with control 
siRNA, nucleofection of MIF siRNA leads to undetectable MIF mRNA in MDF as determined by RT-PCR (c) (N = 4, * P < 0.05).
rMIF treatment of MIF-/- MDF induces p21 expression and nuclear localisationFigure 6
rMIF treatment of MIF-/- MDF induces p21 expression and nuclear localisation. No difference in p21 immunofluo-
rescence was observed when MIF replete wt MDF were treated with rMIF. In contrast, compared with vehicle (V), rMIF 
treated MIF-/- MDF exhibited increased expression and nuclear localisation of p21 (N = 4).
Journal of Inflammation 2009, 6:24 http://www.journal-inflammation.com/content/6/1/24pected permissive role for p21 in normal cell cycle pro-
gression.
In addition to these findings, evidence also exists for p21
as a direct inhibitor of apoptosis, separate from its func-
tion in arrest. Studies examining targeted overexpression
of P21 have shown a significant reduction in induced
apoptosis by interaction with proapoptotic molecules
including procaspase-3, caspase-8 and the kinase apopto-
sis signal-regulating kinase 1 (ASK1) [30-34]. In p21 defi-
cient cells a significant decrease in death receptor
mediated apoptosis, including FAS-dependent apoptosis,
was reported [35]. Furthermore animal studies examining
p21 deficient mice have demonstrated an increased sus-
ceptibility to and aggressiveness of various tumors [36-
39].
The mechanism by which MIF influences the expression
and nuclear localisation of the cell cycle protein p21
requires further elucidation. Several possibilities are sup-
ported in the current literature. The potential for MIF to
impact upon cell cycle via its well described down-regula-
tion of the cell-cycle protein p53 is the subject of many
previous studies [10,11,40,41]. If however the impact of
MIF on p21 is entrained by p53, MIF deficiency with its
attendant increase in p53 protein expression would be
expected to result in increased basal p21 expression.
Accordingly rMIF treatment of cells leading to decreased
p53 expression would be expected to lead to decreased
p21 expression and nuclear localisation. Our results are in
contrast to this and suggest a p53-independent effect of
MIF on p21. Clearly p53 has a powerful impact on both
p21 and cell cycle but this may be more relevant in the set-
ting of immune or oxidative stress rather than during nor-
mal proliferative responses.
We and others have shown MIF-dependant activation of
ERK MAP kinase pathways and reduced ERK and other
MAPK phosphorylation in cells derived from MIF-/- cells
[25,42,43]. Sustained activation of MAPK is known to be
important in cell cycle progression in response to particu-
lar stimuli especially growth factors. For example ERK
pathway activation is required for p21 induction in vascu-
lar smooth muscle cells in response to PDGF [44] and in
keratinocytes in response to TGFb [45]. Further evidence
of MAPK dependant expression of p21 comes from stud-
ies using specific ERK inhibitors [46]. There is also evi-
dence to suggest that MAPK activation leads to
phosphorylation of specific sites on p21 [47].
Studies have shown that MIF is involved in adhesion
dependant signaling and facilitates cell cycle progression
via transcriptional regulation of cyclin D levels [48]. Addi-
tionally it has been demonstrated that MIF-mediated
induction of ERK leads to cyclin D1 transcription [49]. It
is therefore conceivable that p21 expression and nuclear
localisation are influenced by the reduction in cyclin D,
specifically the reduction in available cyclin D to complex
with p21 and CDK2 which would promote nuclear reten-
tion of all three molecules.
The cytokine MIF is increasingly appreciated to play a role
in oncogenic transformation and the promotion of tumor
growth in addition to a broad spectrum of pro-inflamma-
tory actions in a range of tissues and inflammatory dis-
eases. Its validity as a target for therapeutic blockade in a
spectrum of immune-mediated disease in humans is now
well established [50]. Given the broad spectrum of effects
MIF has on the cell cycle, it cannot be assumed that our
observation of reduced proliferation and increased cell
death in the absence of MIF are attributable to modula-
tion of p21 alone. It is however feasible that it may be a
contributing factor to both. The findings in this study sug-
gest that endogenous MIF may be important in the facili-
tation of normal cell growth and that MIF promotes
growth responses and cell viability both basally and in the
setting of oxidative stress, such as SNP. This may be of rel-
evance in the assessment and application of MIF blockade
strategies. The finding of reduced p21 expression and
nuclear localisation in MIF-/- mice and the induction of
p21 nuclear localisation by MIF suggest a novel mecha-
nism, namely the maintenance of basal nuclear p21 lev-
els, by which MIF mediates its permissive effects on cell
growth and cell cycle progression.
p21 localisation is not caused by cycle phase differences in MIF-/- compared with wtFigure 7
p21 localisation is not caused by cycle phase differ-
ences in MIF-/- compared with wt. Cell cycle phase 
assessment using flow cytometric assessment of PI incorpo-
ration. Compared with wt, MIF-/- MDF exhibit no significant 
difference in the percentage of cells in each cell cycle phase. 
Histogram is representative of 4 experiments.Page 8 of 10
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